Cancer genetics and cancer biology

We are using genomic-based approaches to identify DNA mutations and epigenetic modifications associated with different types of cancers. We are performing genome and epigenome analyses in tumours, and are using epigenetic biomarkers to stratify cancer diagnostics. We study the roles of specific regulatory pathways in cancer, including genes encoding hydroxylases.

Key researchers

We are using genome wide approaches to study the deregulation of epigenetic and gene regulation networks in acute myeloid leukaemia as compared to normal blood progenitor cells. We are performing intensive analyses of the mechanisms utilised by specific mutations in such commonly mutated genes as RUNX1, FLT3 and LMO2. We are also investigating how leukaemia is maintained by over-expression of factors such as MYB.

Key researchers

Defects in the replication and repair of DNA are major contributors to the development of cancer. These processes are also major targets of chemotherapy in cancer. We have an extensive programme of research where several different research teams work closely on the regulation of DNA replication and repair. Our research interests include the role of post translational modifications in the regulation of DNA replication and repair and the role it plays in maintaining genome stability. We are also investigating the role of tumour suppressors and oncogenes, and the influence of ongoing transcription, in replication stress.

Key researchers

Specific mutations in genes that control DNA replication and repair can lead to error prone replication and the accumulation of errors. We are investigating the roles of mutations of these genes which include ATM, BRCA1, BRCA2 and PALB2. Processes that protect genome integrity are also central to the actions of many DNA damaging anti-cancer therapeutics and we are exploring these pathways for potential therapeutic targets. We are also investigating how some genes such as MYBL2 are essential for the maintenance of genome stability.

Key researchers

The aim of our Viral Oncology research programme is to elucidate the molecular and cellular mechanisms by which tumour viruses cause malignant and non-malignant disease. Viruses underlie several types of cancer. These include Epstein Barr virus in B cell tumours and human papilloma virus in cervical cancer and head and neck cancers. We are also studying the mechanisms used by adenovirus oncoproteins to transform cells.

Key researchers

We are investigating the cellular and molecular basis of breast cancer from many different angles. We are identifying mechanisms whereby DNA mutations deregulate transcription signalling, or generate additional mutations by promoting DNA damage. We are also working in the clinic to improve the treatment of breast cancer, as well as studying how breast cancer cells break away from tumours to form metastases.

Key researchers

We cooperate across the hospital/university campus to deliver comprehensive research programmes that span the full range of cancer diagnosis, molecular investigations of cancer cells, and delivery of cancer treatments. The Cancer Research UK Clinical Trials Unit is a world leader in the development and assessment of new cancer therapies.

Our aims are to develop new tools for diagnosing and treating cancer. We are developing new screening tools, and evaluating different therapies. These aims are supported by our laboratory studies that identify biomarkers and molecular defects in cancer cells. We have made significant advances in many areas which include colorectal cancer, bladder cancer and leukaemia.

Key researchers